Ir J Med Sci. 2025 Dec 5. doi: 10.1007/s11845-025-04221-x. Online ahead of print.ABSTRACTINTRODUCTION: The estimated glomerular filtration rate (eGFR) calculated from serum creatinine has limitations in accurately reflecting kidney function due to its dependence on muscle mass and non-GFR determinan
Mol Cell Biochem. 2025 Dec 5. doi: 10.1007/s11010-025-05447-0. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is a comprehensive disease characterized by renal injury and decreased renal function, which can lead to increased cardiovascular and all cause mortality rates, seriously affecti
Egypt Heart J. 2025 Dec 5;77(1):109. doi: 10.1186/s43044-025-00707-2.ABSTRACTBACKGROUND: Although the hemoglobin-to-creatinine ratio (HCR) has been recognized as a predictor for various diseases, its prognostic value in patients with coronary artery disease (CAD) remains unclear. This study aimed to
Sleep Breath. 2025 Dec 5;30(1):4. doi: 10.1007/s11325-025-03540-8.ABSTRACTPURPOSE: Sleep-disordered breathing (SDB) is a risk factor of ischemic stroke but can also appear "de novo" after the acute brain damage. The link between SDB and stroke topography, which remains controversial, was assessed in
JAMA Netw Open. 2025 Dec 1;8(12):e2547119. doi: 10.1001/jamanetworkopen.2025.47119.ABSTRACTIMPORTANCE: Place-based Climate Vulnerability Index (CVI) may shape metabolic risk through environmental and socioeconomic stressors, but its association with incident type 2 diabetes (T2D) is not well charact
Mol Genet Genomics. 2025 Dec 5;300(1):110. doi: 10.1007/s00438-025-02323-w.ABSTRACTDiabetic cardiomyopathy (DCM) significantly contributes to cardiovascular complications in diabetes. This study investigated the protective effects of Resveratrol (RES) in combination with evidence-based nursing on DC
J Wound Care. 2025 Dec 2;34(12):961-969. doi: 10.12968/jowc.2025.0486.ABSTRACTOBJECTIVE: To evaluate the performance and safety of Biatain Fiber Ag (Coloplast A/S, Denmark), a new gelling fibre wound dressing containing silver, in venous leg ulcers (VLUs) after four weeks of treatment.METHOD: This n
J Wound Care. 2025 Dec 2;34(12):982-990. doi: 10.12968/jowc.2024.0015.ABSTRACTOBJECTIVE: To evaluate the incremental cost-effectiveness and cost-utility ratios (ICER; ICUR) of a single-layer high compression bandage (SLHCB) compared with Unna's boot (UB) from the perspective of the Brazilian healthc
J Wound Care. 2025 Dec 2;34(12):1013-1022. doi: 10.12968/jowc.2023.0158.ABSTRACTOBJECTIVE: To evaluate the effectiveness of telemedicine in home healthcare for patients with diabetic foot ulcers (DFUs) on wound healing time, wound score and patient self-management.METHOD: Participants with DFUs were
Neurosurg Rev. 2025 Dec 5;49(1):50. doi: 10.1007/s10143-025-03978-0.ABSTRACTIntracranial atherosclerosis (ICAS) is a leading cause of ischemic stroke (IS). Conventional imaging poorly reflects plaque activity, whereas arterial wall enhancement on high-resolution MR vessel-wall imaging (HRMR-VWI) may
JACC Case Rep. 2025 Dec 4:106251. doi: 10.1016/j.jaccas.2025.106251. Online ahead of print.ABSTRACTBACKGROUND: Systemic lupus erythematosus (SLE) markedly increases cardiovascular risk through inflammation and thrombophilia, which may be further intensified by antiphospholipid syndrome (APS).CASE SU
J Am Coll Cardiol. 2025 Nov 18:S0735-1097(25)10068-5. doi: 10.1016/j.jacc.2025.10.057. Online ahead of print.ABSTRACTBACKGROUND: For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):324-333. doi: 10.1182/hematology.2025000721.ABSTRACTThe introduction of CAR (chimeric antigen receptor) T-cell therapy and bispecific antibodies into clinical practice has revolutionized the treatment landscape of relapsed/refractory multipl
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):61-71. doi: 10.1182/hematology.2025000688.ABSTRACTHematologic malignancies are associated with an increased risk of venous thromboembolism (VTE) with aggressive lymphomas and multiple myeloma exhibiting the highest VTE incidence. The perform
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):674-681. doi: 10.1182/hematology.2025000773.ABSTRACTAdvances in the development of safe and effective treatments for hemophilia over the past century have significantly increased the life expectancy of persons with hemophilia (PwH). As a res
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):645-651. doi: 10.1182/hematology.2025000761.ABSTRACTIndefinite maintenance therapy, typically with lenalidomide, remains a standard of care for patients with multiple myeloma, largely based on studies that demonstrated improved progression-f
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):652-658. doi: 10.1182/hematology.2025000762.ABSTRACTDespite the enormous progress made in the treatment of multiple myeloma (MM) with various treatment choices in frontline and relapse settings, treatment of high-risk (HR)MM remains a therap
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):401-404. doi: 10.1182/hematology.2025000730.ABSTRACTQuadruplet induction regimens containing anti-CD38 monoclonal antibodies in combination with a triplet backbone are providing deeper and more durable responses in newly diagnosed multiple m
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):405-411. doi: 10.1182/hematology.2025000731.ABSTRACTMultiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematologic malignancy. With treatment advances, patients are living longer. However, the disease remains incura
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):412-423. doi: 10.1182/hematology.2025000732.ABSTRACTWhile lenalidomide has been the established standard of care for maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma, risk-adapted maintenance strateg
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):72-79. doi: 10.1182/hematology.2025000689.ABSTRACTVenous thromboembolism (VTE) is a frequent complication in patients with cancer, especially those receiving systemic therapy in the ambulatory setting. Despite being a largely preventable con
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):682-690. doi: 10.1182/hematology.2025000766.ABSTRACTPrecursor states such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance, carry distinct risks for progression to myeloid neoplasms
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):22-33. doi: 10.1182/hematology.2025000683.ABSTRACTArterial and venous thromboses differ in pathophysiology but share overlapping risk factors such as obesity, metabolic syndrome, and aging. Patients with established arterial disease, such as
Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):285-290. doi: 10.1182/hematology.2025000716.ABSTRACTAlthough the management of β-thalassemia has improved significantly, patients still suffer from many complications, including thrombotic events. A hypercoagulable state has been demonstrate
